Skyrizi and Glaucoma - a phase IV clinical study of FDA data

Summary:

Glaucoma is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Losartan, and have Psoriasis.

The phase IV clinical study analyzes which people have Glaucoma when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,233 drugs and 1,657 conditions by eHealthMe. Check the latest studies of Glaucoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 46 people (0.1%) have Glaucoma.

Among these 46 people:

How long have people been on Skyrizi when they have Glaucoma? *

What is the gender of people who have Glaucoma when taking Skyrizi? *

female: 71.74 %
male: 28.26 %

What is the age of people who have Glaucoma when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

What are other side effects people have besides Glaucoma? *

Cataract (clouding of the lens inside the eye): 15 people, 32.61%
Visual Impairment: 6 people, 13.04%
Itching: 5 people, 10.87%
Psoriasis (immune-mediated disease that affects the skin): 5 people, 10.87%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 4 people, 8.70%
Skin Disorder (skin disease): 4 people, 8.70%
Ureteric Obstruction: 3 people, 6.52%
Oedema Peripheral (superficial swelling): 3 people, 6.52%
Pain In Extremity: 3 people, 6.52%
Diabetes: 3 people, 6.52%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 44 people, 95.65%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 10.87%
Chest Pain: 3 people, 6.52%
Thyroid Diseases: 2 people, 4.35%
Depression: 2 people, 4.35%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 2.17%
High Blood Cholesterol: 1 person, 2.17%
Gastritis (inflammation of stomach): 1 person, 2.17%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 2.17%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Glaucoma?

- Check whether Glaucoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Glaucoma treatments and more:

Glaucoma (61,928 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glaucoma:

Glaucoma (1,233 drugs)

Browse all the conditions that are associated with Glaucoma:

Glaucoma (1,657 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.